Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: mike head who wrote (5259)	1/6/1998 7:40:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 17367

Thanks Mike. I've been posting some speculation on the IDEC (IDPH) thread about the possible success of their Rituxan antibody. As you may know Xoma was the first to make, and patent, chimeric anti-CD20 antibodies, of which Rituxan is but an example. And IDEC (and its Rituxan partner, Genentech) has agreed to pay Xoma royalties on sales for the right to use this technology. The first quarter reports for Xoma and IDEC will be interesting, for a change, as we can start to assess the size of Rituxan's market and the exact royalty stream Xoma will be getting from this. And you are more than correct in making a difference between the Chicano brand of Spanish and what's spoken in other countries. I've had housemates from Argentina, Spain, Puerto Rico, among others, and some times it was hard to agree on what the "correct" way of saying things was. Of course, the Spaniards were always right (they are our British equivalents -g-). PB